Antiplatelet drug

PhaseBio Announces Dosing of First Patient in European Union as Part of REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor

Retrieved on: 
Thursday, January 28, 2021

Bentracimab is a novel, human monoclonal antibody fragment that in earlier clinical trials has shown immediate and sustained reversal of the antiplatelet effects of Brilinta (ticagrelor).

Key Points: 
  • Bentracimab is a novel, human monoclonal antibody fragment that in earlier clinical trials has shown immediate and sustained reversal of the antiplatelet effects of Brilinta (ticagrelor).
  • We are pleased to announce the expansion of our global Phase 3 study of bentracimab into a number of European Union countries.
  • Additionally, in a translational study, bentracimab achieved equivalent reversal of branded ticagrelor and multiple ticagrelor generics.
  • Additionally, the Phase 2a trial investigated a bentracimab regimen for the reversal of supratherapeutic doses of ticagrelor in healthy younger subjects.

CHMP recommends approval of Plavix® (clopidogrel) with aspirin in adults for certain types of strokes

Retrieved on: 
Friday, December 11, 2020

This new indication includes Plavix used alongside aspirin within 24 hours of an event and continued for 21 days, followed by long-term single anti-platelet therapy.

Key Points: 
  • This new indication includes Plavix used alongside aspirin within 24 hours of an event and continued for 21 days, followed by long-term single anti-platelet therapy.
  • Following this CHMP positive opinion, a final decision about the new, expanded indication is anticipated in Q1 2021.
  • We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
  • With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

PhaseBio Doses First Patients in Canada as Part of the REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of the Antiplatelet Effects of Ticagrelor

Retrieved on: 
Tuesday, October 6, 2020

Bentracimab is a novel, human monoclonal antibody fragment that in earlier trials has shown immediate and sustained reversal of the antiplatelet effects of Brilinta (ticagrelor).

Key Points: 
  • Bentracimab is a novel, human monoclonal antibody fragment that in earlier trials has shown immediate and sustained reversal of the antiplatelet effects of Brilinta (ticagrelor).
  • We view the expansion of REVERSE-IT enrollment into Canada as an important milestone for the global bentracimab program.
  • Patients with reported use of ticagrelor within the prior 3 days who require urgent ticagrelor reversal will be eligible for enrollment.
  • Additionally, the Phase 2a trial investigated a bentracimab regimen for the reversal of supratherapeutic doses of ticagrelor in healthy younger subjects.

Aging Populations Will Increase Demand in the $35,802 Million Antithrombotic Drugs Market, Reports TBRC

Retrieved on: 
Thursday, April 16, 2020

Read More On The Business Research Company's Antithrombotic Drugs Market Report: https://www.thebusinessresearchcompany.com/report/antithrombotic-drugs-m...

Key Points: 
  • Read More On The Business Research Company's Antithrombotic Drugs Market Report: https://www.thebusinessresearchcompany.com/report/antithrombotic-drugs-m...
    The global antithrombotic drugs market reached a value of nearly $35,801.9 million in 2019.
  • Request A Sample Of The Antithrombotic Drugs Market Report: https://www.thebusinessresearchcompany.com/sample.aspx?id=2411&type=smp
    The antithrombotic drugs market consists of sales of antithrombotic drugs by entities (organizations, sole traders and partnerships) that manufacture antithrombotic drugs which are used to prevent and treat arterial and venous thrombosis, and reduce the formation of clots.
  • The antithrombotic drug industry includes establishments that manufacture anti-thrombotic drugs such as anticoagulants, antiplatelets and thrombolytic drugs.
  • The antithrombotic drugs market is segmented by type into anti-coagulant drugs, anti-fibrinolytics drugs, and anti-platelet drugs.

PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® for PB2452

Retrieved on: 
Friday, January 10, 2020

The collaboration between SFJ and PhaseBio will support the global development of PB2452, which is designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations.

Key Points: 
  • The collaboration between SFJ and PhaseBio will support the global development of PB2452, which is designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations.
  • This innovative collaboration with SFJ provides PhaseBio with substantial funding to continue the rapid advancement of our lead program, PB2452, and enables us to efficiently extend our global reach, said Jonathan P. Mow, Chief Executive Officer of PhaseBio.
  • The collaboration provides PhaseBio with financial flexibility while allowing us to retain full commercial rights and mitigate our global development risk.
  • In general, the amount to be repaid by PhaseBio will not exceed five times the amount funded by SFJ.

OTITOPIC™ Announces Results of Dose-Finding PK/PD Study for ASPRIHALE® Dry Powder Inhalation of Aspirin for Acute Myocardial Infarction (MI)

Retrieved on: 
Thursday, January 2, 2020

OTITOPIC, a leader in the development of pharmaceutical dry powder inhalation of aspirin technology, today announced the results of a dose-finding PK study of its inhalable aspirin.

Key Points: 
  • OTITOPIC, a leader in the development of pharmaceutical dry powder inhalation of aspirin technology, today announced the results of a dose-finding PK study of its inhalable aspirin.
  • Kambiz Yadidi, President of Otitopic, said: We are proud to successfully conclude the clinical studies with ASPRIHALE, our first-in-class dry powder inhalation of aspirin to treat suspected acute MI.
  • Otitopic is pioneering a new class of dry powder inhalation in the cardiovascular field, based on the companys proprietary drug delivery platform.
  • Otitopic is dedicated to making better anti-platelet treatment, to provide high-risk MI patients with a faster-acting alternative for management of suspected acute MI.

Spartan Bioscience and Angiocare Partner to Bring the World's First Rapid Precision Medicine DNA Test to Cardiac Stent Patients in Europe

Retrieved on: 
Thursday, December 5, 2019

(5) For heart attack patients, most complications from poor Plavix response occur in the first 24-48 hours after cardiac stenting.

Key Points: 
  • (5) For heart attack patients, most complications from poor Plavix response occur in the first 24-48 hours after cardiac stenting.
  • (6,7) Spartan's rapid, portable test allows real-time, near patient determination of the patient's genotype, aiding in determining the appropriate antiplatelet treatment.
  • and CEO of Spartan Bioscience, said, "We are looking forward to our partnership with Angiocare.
  • The Spartan logo is a registered trademark of Spartan Bioscience Inc.
    Plavix is a registered trademark of Bristol-Myers Squibb/Sanofi Pharmaceuticals.

Positive Data from First Clinical Study of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor Designed for First Point-of-Contact STEMI Therapy, Presented at AHA 2019 Late-Breaking Science Session

Retrieved on: 
Monday, November 11, 2019

Inhibiting platelet aggregation can slow or stop blood clot formation leading to coronary artery blockage, and in turn, can stop or prevent a heart attack.

Key Points: 
  • Inhibiting platelet aggregation can slow or stop blood clot formation leading to coronary artery blockage, and in turn, can stop or prevent a heart attack.
  • By targeting platelet GPIIb/IIIa receptors, the final common pathway in platelet aggregation, RUC-4 inhibits platelet aggregation caused by all platelet activators and can, under some conditions, promote platelet disaggregation (clot dissolution).
  • In contrast, other antiplatelet medications, including P2Y12 inhibitors and aspirin, inhibit only one platelet activator and do not disaggregate existing clots.
  • Further, oral P2Y12 inhibitors do not act rapidly or reliably enough in STEMI patients during the crucial early minutes of a heart attack.

CALQUENCE® Data To Show Improved Progression-Free Survival In Phase III Front-Line Chronic Lymphocytic Leukemia At ASH 2019 Annual Meeting

Retrieved on: 
Wednesday, November 6, 2019

Serious hemorrhagic events, including fatal events, have occurred in the combined safety database of 612 patients with hematologic malignancies treated with CALQUENCE monotherapy.

Key Points: 
  • Serious hemorrhagic events, including fatal events, have occurred in the combined safety database of 612 patients with hematologic malignancies treated with CALQUENCE monotherapy.
  • CALQUENCE may further increase the risk of hemorrhage in patients receiving antiplatelet or anticoagulant therapies, and patients should be monitored for signs of bleeding.
  • Consider the benefit-risk of withholding CALQUENCE for 3 to 7 days pre- and post-surgery, depending upon the type of surgery and the risk of bleeding.
  • Moderate CYP3A Inhibitors: When CALQUENCE is co-administered with a moderate CYP3A inhibitor, reduce CALQUENCE dose to 100 mg once daily.

PhaseBio Expands Executive Management Team

Retrieved on: 
Thursday, October 24, 2019

PhaseBio has achieved critical milestones this year and is making solid progress in the advancement of PB2452, a novel agent for the reversal of the antiplatelet activity of ticagrelor, said Jonathan P. Mow, Chief Executive Officer of PhaseBio.

Key Points: 
  • PhaseBio has achieved critical milestones this year and is making solid progress in the advancement of PB2452, a novel agent for the reversal of the antiplatelet activity of ticagrelor, said Jonathan P. Mow, Chief Executive Officer of PhaseBio.
  • These additions to our management team allow us to more efficiently prepare for the submission of a Biologics License Application for PB2452 and for potential accelerated approval and commercial launch.
  • We are delighted to welcome Kris and Glen, two seasoned leaders with extensive biopharmaceutical industry experience, to the team.
  • Prior to joining PhaseBio, Mr. Hanson served as Vice President, Legal & Compliance and Head of Human Resources for Nalpropion Pharmaceuticals where, as a member of the companys executive management team, he had responsibility for the company's legal, compliance and human resources functions.